Physician profile
Catherine M Compton
NPI 1457883415
$1,257.21
in general payments reported to CMS, 2019-2025
19 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $179 · 2023: $305 · 2024: $464 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $305.23 | 2021-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $262.35 | 2023-2024 | Vraylar |
| Novartis Pharmaceuticals Corporation | $80.00 | 2022-2023 | |
| Glaxosmithkline, LLC. | $71.23 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.84 | 2022-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.98 | 2025 | Caplyta |
| Lilly USA, LLC | $54.96 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $50.79 | 2023-2025 | Airsupra, Breztri |
| Abbott Laboratories | $44.39 | 2021-2022 | |
| Amgen INC. | $40.22 | 2024 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $35.79 | 2022 | |
| Pfizer INC. | $34.63 | 2022-2024 | |
| Exact Sciences Corporation | $29.21 | 2023 | Cologuard Collection Kit |
| Organon LLC | $26.29 | 2023 | Nexplanon |
| Astellas Pharma US INC | $25.26 | 2024 | Veozah |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $23.20 | 2022 | |
| Axsome Therapeutics, INC. | $15.65 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $15.03 | 2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $14.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Compton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.